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OAR dose tolerance. No relationship was identified between 
the % difference of OAR volumes and D2cc OAR % variations. 
 
Conclusion: Patients treated with 45Gy in 25 fractions EBRT 
+ 21Gy in 3 fractions VBT are at greater risk of breaching OAR 
dose tolerances when using a single planning scan for all 
treatments. There is no significant relationship between the 
% difference of bladder, rectum, sigmoid and small bowel 
volumes and % dose difference. The OAR dose variation 
between each scan is most likely due to the unpredictable 
day to day movement of the structure and cannot be 
replicated by standardised organ filling procedures. 
Departmental protocols have been amended to CT plan this 
subgroup of patients before each treatment fraction to take 
into account position of structure at that time. Use of a 
multichannel applicator could also help minimise the dose to 
these structures. 
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Purpose or Objective: A report of late rectal and bladder 
toxicitiy outcomes of a computed tomography(CT)-based 
image guided brachytherapy(IGBT) technique for treatment 
of cervical cancer.  
 
Material and Methods: Between 2008-2014, 95 women with 
International Federation of Gynecology and Obstetrics stage 
IB to IVA cervical carcinoma treated with definitive 
concurrent cisplatin based chemotherapy and external beam 
radiation therapy (EBRT) 50.4Gy in 28 fractions followed by 
3-4 fractions of high-dose-rate (HDR) IGBT was 
retrospectively reviewed. At each implantation, all patients 
had a urinary catheter insitu and received bowel enema 
before undergoing planning CT-simulation. A high-risk clinical 
target volume (HRCTV) encompassing any visible tumor and 
the entire cervix, rectum and bladder was contoured on the 
simulation CT according to Radiation Therapy Oncology Group 
Gynaecology Contouring Atlas. Prescription dose range of 5.5-
7Gy was prescribed to the HRCTV. Doses to Point A, ICRU 
rectal and bladder points were recorded. Toxicities were 
recorded using NCI-CTCAE version 3. 
 
Results: The median follow-up time was 29 months. The 
mean Point A dose was 6Gy (4.6-7.6Gy). The ICRU rectum and 
bladder points were 4.69Gy (2.5-5.7Gy) and 4.23Gy (1.95-
7.2Gy) respectively. 22 patients(23%) and Grade 2 proctitis 
and 10 patients(11%) had Grade 3 proctitis. 4 patients (4%) 
had Grade 2 cystits and 2 patients(2%) had Grade 3 cystitis. 
No patients had ≥ Grade 4 toxicity.  
 
Conclusion: Despite bladder and bowel preparation protocol, 
late rectal toxicity was significant in a high proportion of 
patients. Implementation of an interstitial IGBT using the 
EMBRACE protocol might help to limit these late rectal 
toxicities. 
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Purpose or Objective: To analyze the preliminary results of 
a new daily high-dose-rate brachytherapy (BT) schedule in 
vaginal-cuff relapse (VCR) and toxicity in postoperative 
endometrial carcinoma (EC). 
 
Material and Methods: From September 2011 to December 
2014, 102 patients (p) were treated with HDRBT in FIGO 
stages: IA-30p, IB-39p, II-8p, IIIA-4p, IIIB-1p, IIIC1-8p, IIIC2-
5p, IIIC3-1p, IVB-6p. Pathology: 79/102 endometrioid 
adenocarcinoma and 23/102 other types. Radiotherapy: 
Group 1: 74p/102p 1 BT fraction of 7Gy after external beam 
irradiation (mean 45Gy, range 44.0-50.4); Group 2: 28p/102p 
BT alone by 3 daily fractions of 6Gy. Chemotherapy: 20/102 
patients. Toxicity evaluation: RTOG scores for bladder and 
rectum and the objective criteria of LENT-SOMA for vagina. 
Statistics: Chi-square and Fisher exact tests. 
 
Results: Mean age (years): Group 1: 65.4 (40-88), Group 2: 
66.7 (39-90). Mean follow-up (months): Group 1: 24.48 (8.04-
52.56); Group 2: 26.88 (8.76-54.48). VCR: No relapses with 
the present mean follow-up. Toxicity: Group 1 - early 
problems (all G1-2) in rectum (5.5%), bladder (6.8%) and 
vagina (14.9%). Late toxicities: rectum 2.7% (all G1), bladder 
0% and vagina 27% (G1-G2). Group 2 -early toxicity: bladder 
10.7% (all G1), vagina 28.1% (all G1-G2), rectum 0%; late 
toxicity was only found in vagina in 17.8% (G1-2). No 
significant differences were found in toxicities between the 
two groups. 
 
Conclusion: The present brachytherapy schedule consisting 
in 1 fraction/7Gy after external beam irradiation and 3 
fractions/6Gy administered daily seem a safe regime in terms 
of local control and toxicity for postoperative EC. These 
results seem similar to those found in our Hospital in 2 
previous series with low dose per fraction and an increased 
number of fractions. Grant: AECC Foundation 
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Purpose or Objective: To develop a reliable method of 
determining the radiation dose to the vaginal mucosa in the 
treatment of cervical cancer. 
 
Material and Methods: Forty six cervical cancer patients 
were treated with EBRT and HDR brachytherapy therapy from 
July 2010 – Dec 2013. They received 45Gy in 25 fractions of 
EBRT to the entire pelvis followed by 3 HDR brachytherapy 
fractions using a tandem and ring applicator with a HRCTV 
D90 of 80-85Gy. A volume to represent the vaginal mucosa 
was obtained by using a non-uniform expansion of the 5mm 
ring applicator cap; this was expanded by 5.0 mm in all 
directions except the sup/inf which was expanded by 7.0 
mm. In addition, a rectal vaginal (RV) point dose was 
determined using a point 5.0 mm posterior to the 
intersection of the superior-posterior junction of the build up 
cap (figure 1 sagittal view). Total doses were calculated for 
vaginal volumes of 5.0cc (D5 v), 2.0cc (D2 v), and the RV 
point. In addition, the slope was calculated for the vaginal 
mucosa between D5 v and D2 v. Pearson correlation 
coefficients (with p values = 0.01) were assessed to identify 
